Verano Holdings VRNO
OTC VRNO
$6.21 +0.16 (+2.64%)
As of: Aug 21, 2026 · 3:59 PM EDT

Verano Holdings (VRNO) Asset Writedowns and Impairment (2021 - 2026)

Verano Holdings (VRNO) posted quarterly Asset Writedowns and Impairment of $177.4 million for Q4 2025, down 45.85% year-over-year from $327.7 million in Q4 2024, and up 3185.93% quarter-over-quarter from $5.4 million in Q3 2025.

Verano Holdings (VRNO) Asset Writedowns and Impairment (2021 - 2026) Analysis & Trends

Verano Holdings (VRNO) has reported Asset Writedowns and Impairment for 5 consecutive years, with $177.4 million the latest figure, recorded in Q4 2025.

  • In Q4 2025, Asset Writedowns and Impairment fell 45.85% year-over-year to $177.4 million; the TTM figure through Dec 2025 stood at $511.0 million (up 55.87% YoY), while the FY2025 annual figure was $183.3 million, down 44.07% from the prior year.
  • Asset Writedowns and Impairment advanced to $177.4 million in Q4 2025 per VRNO's latest filing, from $5.4 million in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $327.7 million in Q4 2024 and bottomed at -$2.2 million in Q4 2022.
  • Historically, Asset Writedowns and Impairment has averaged $43.1 million across 5 years, with a median of $510500.0 in 2023.
  • Annual changes were most pronounced in 2022 — Asset Writedowns and Impairment tumbled 2468.24% — and 2023, when it slipped 12.02%.
  • Verano Holdings' Asset Writedowns and Impairment stood at -$85000.0 in 2021, then slumped by 2468.24% to -$2.2 million in 2022, then jumped by 401.01% to $6.6 million in 2023, then jumped by 4887.05% to $327.7 million in 2024, then sank by 45.85% to $177.4 million in 2025.
  • Business Quant data shows VRNO's Asset Writedowns and Impairment at $177.4 million in Q4 2025, $5.4 million in Q3 2025, and $428000.0 in Q2 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Haleon 44.51 Bn 43.55 Bn -
2 Teva Pharmaceutical Industries 43.52 Bn 39.86 Bn 2.15 Bn
3 Zoetis 32.43 Bn 30.75 Bn 1.05 Bn
4 Takeda Pharmaceutical 28.63 Bn 22.83 Bn 5.10 Bn
5 United Therapeutics 21.87 Bn 19.21 Bn 683.80 Mn
6 Viatris 18.98 Bn 18.09 Bn 1.46 Bn
7 Neurocrine Biosciences 15.43 Bn 15.04 Bn 935.80 Mn
8 Elanco Animal Health 12.02 Bn 11.49 Bn 798.00 Mn
9 Dr Reddys Laboratories 10.14 Bn 9.98 Bn -
10 Verano Holdings 449.04 Mn 363.85 Mn 99.70 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 4.06 Mn
Jun 30, 2026 4.06 Mn
Dec 31, 2025 177.44 Mn
Dec 31, 2025 177.44 Mn
Sep 30, 2025 5.40 Mn
Sep 30, 2025 5.40 Mn
Jun 30, 2025 428,000.00
Jun 30, 2025 428,000.00
Dec 31, 2024 327.70 Mn
Dec 31, 2024 327.70 Mn
Mar 31, 2024 112,000.00
Mar 31, 2024 112,000.00
Sep 30, 2023 6.57 Mn
Sep 30, 2023 6.57 Mn
Mar 31, 2023 593,000.00
Mar 31, 2023 593,000.00
Dec 31, 2022 -2.18 Mn
Dec 31, 2022 -2.18 Mn
Jun 30, 2022 342,000.00
Jun 30, 2022 342,000.00